Paromomycin sulfate is aminoglycoside sulfate salt, which is the result of the treatment of paromomycin with sulfuric acid. It is a type of antimicrobial medicine, which is used to treat acute and chronic intestinal amoebiasis. Amebiasis is a bowel infection caused by parasite present in the bowels or the stomach. I addition, it is used for various other parasitic infections such as giardiasis, leishmaniasis, and tapeworm infection. This medicine is further used with other drugs in order to lessen the symptoms of a complicated liver disease known as hepatic coma.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the paromomycin sulfate market.
Top Impacting Factors
- Rise in the geriatric population with chronic intestinal and bowel disorder is the key a few factor that drives the growth of the paromomycin sulfate market.
- In addition, rise in adopting of sedentary lifestyle leads to gastrointestinal diseases, which increases the demand of paromomycin sulfate, thus propelling the growth of the market.
- However, side effects such as vomiting and loss of appetite are common, which will slow the growth rate of the paromomycin sulfate market.
- Conversely, rise in awareness among population for use of medication available for acute bowel disorders paves the way for new opportunities in the paromomycin sulfate market.
Market Trends
New product launches to flourish the market
In 2019, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, launched Mucaine Gel Syrup to treat hyperacidity, heartburn, upset stomach, and ulcer.
Key Benefits of the Report
- This study presents the analytical depiction of the paromomycin sulfate industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years
Questions Answered in the Paromomycin Sulfate Report
- Which are the leading players active in the paromomycin sulfate market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "paromomycin sulfate"?
- What is "paromomycin sulfate" market prediction in the future?
Paromomycin Sulfate Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | ERFA Canada,, Kaifeng Pharm., Shanhe Pharm,, Pfizer,, Changrui Pharm, |
Loading Table Of Content...
